According to media reports, Sharps Technology completed its Private round of financing on August 25, 2025. The round saw participation from Pantera Capital, ParaFi Capital, Borderless Capital, CoinFund, Arrington Capital, Primitive Ventures, Hypersphere Ventures, FalconX, RockawayX, and Quantstamp.Sharps Technology, listed on NASDAQ under the ticker STSS, is a medical device company specializing in the development and manufacturing of innovative safety syringes. The company's core mission is to leverage its technology to reduce the risk of disease transmission caused by needlestick injuries, safeguarding healthcare professionals, patients, and the public, while enhancing the accuracy and efficiency of drug delivery.Latest reports indicate that on August 25, 2025, Sharps Technology completed a PIPE private placement raising over $400 million, designated for establishing a SOL treasury. Subsequently, on August 29, 2025, the company expanded the financing to $1 billion and launched a digital asset reserve strategy. By September 2, 2025, Sharps Technology’s SOL holdings exceeded 2 million tokens, demonstrating the company’s active engagement and robust momentum in the digital asset sector.This series of financing and strategic initiatives highlights Sharps Technology’s proactive embrace of new technologies and business models as a traditional medical device company, underscoring its ambitions in medical technology innovation and digital asset management.